Population-level impact of weight loss on predicted healthcare spending and the incidence of obesity-related outcomes in the Asia-Pacific region: a modelling study

Table 2 Direct medical costs in 2022 and in 10 years (no-intervention scenario)

		2022			2032
Country	Obese population	Direct medical costs^POPN (USD)	Cost per person (USD)	Proportion of GDP (%)	Direct medical costs^POPN (USD)	Cost per person (USD)
Australia^a	5.2 million	2.9 billion	558	0.21%	6.9 billion	1410
South Korea^a	13.8 million	7.5 billion	545	0.46%	18.4 billion	1397
Thailand^a	14.9 million	10.2 billion	685	2.1%	23.5 billion	1649
India^b	223 million	23.3 billion	104	0.86%	44.3 billion	207

GDP gross domestic product, POPN population, USD United States dollars
^aCosts estimated for Australia, South Korea, and Thailand factor the direct medical costs of ten obesity-related comorbidities—diabetes, hypertension, dyslipidaemia, heart failure, atrial fibrillation, unstable angina/myocardial infarction, hip/knee osteoarthritis, asthma, sleep apnoea, and chronic kidney disease
^bCosts estimated for India only factors in six out of the ten obesity-related comorbidities factored in this model. Sleep apnoea, dyslipidaemia, atrial fibrillation and flutter, and unstable angina are excluded owing to data inconsistencies/limitations

ISSN: 2731-913X